Trial Profile
Candesartan and candesartan/ hydrochlorothiazide in the treatment of patients with essential hypertension and a concomitant disease left ventricular hypertrophy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2008
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary) ; Candesartan cilexetil/hydrochlorothiazide (Primary)
- Indications Essential hypertension; Left ventricular hypertrophy
- Focus Therapeutic Use
- Acronyms CandLE
- Sponsors AstraZeneca
- 11 Mar 2008 New trial record.